All In Biotech

Drug Trial Radar · NCT07314242

A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD

A Randomized, Double-blind, Single-dummy, Positive Drug and Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Evaluate the Efficacy and Safety of Hemay005 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, Randomized, Double-blind, Single-dummy, positive drug and placebo-controlled, Parallel Group, Phase 2a Study to Evaluate the Efficacy and Safety of Hemay005 in Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • Hemay005 tabletsDrug

    Subjects take Hemay005 tablets for 12 weeks.

  • Roflumilast Oral TabletDrug

    Subjects take roflumilast tablet for 12 weeks.

  • Placebo tabletDrug

    Subjects take placebo tablet for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sputum biomarkersTime frame: Change from baseline to week 4
  2. Sputum cell countTime frame: Change from baseline to week 4
  3. Blood BiomarkersTime frame: Change from baseline to week 4

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Tianjin Fourth Central Hospital

    Tianjin, China

  • China People's Armed Police Force Characteristic Medical Center

    Tianjin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.